Literature DB >> 27188943

Reevaluating Cumulative HIV-1 Viral Load as a Prognostic Predictor: Predicting Opportunistic Infection Incidence and Mortality in a Ugandan Cohort.

Joseph B Sempa, Jonathan Dushoff, Michael J Daniels, Barbara Castelnuovo, Agnes N Kiragga, Martin Nieuwoudt, Steven E Bellan.   

Abstract

Recent studies have evaluated cumulative human immunodeficiency virus type 1 (HIV-1) viral load (cVL) for predicting disease outcomes, with discrepant results. We reviewed the disparate methodological approaches taken and evaluated the prognostic utility of cVL in a resource-limited setting. Using data on the Infectious Diseases Institute (Makerere University, Kampala, Uganda) cohort, who initiated antiretroviral therapy in 2004-2005 and were followed up for 9 years, we calculated patients' time-updated cVL by summing the area under their viral load curves on either a linear scale (cVL1) or a logarithmic scale (cVL2). Using Cox proportional hazards models, we evaluated both metrics as predictors of incident opportunistic infections and mortality. Among 489 patients analyzed, neither cVL measure was a statistically significant predictor of opportunistic infection risk. In contrast, cVL2 (but not cVL1) was a statistically significant predictor of mortality, with each log10 increase corresponding to a 1.63-fold (95% confidence interval: 1.02, 2.60) elevation in mortality risk when cVL2 was accumulated from baseline. However, whether cVL is predictive or not hinges on difficult choices surrounding the cVL metric and statistical model employed. Previous studies may have suffered from confounding bias due to their focus on cVL1, which strongly correlates with other variables. Further methodological development is needed to illuminate whether the inconsistent predictive utility of cVL arises from causal relationships or from statistical artifacts.
© The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cox proportional hazards models; HIV; Martingale residuals; human immunodeficiency virus; mortality; opportunistic infections; viral load; viremia copy-years

Mesh:

Substances:

Year:  2016        PMID: 27188943      PMCID: PMC4929240          DOI: 10.1093/aje/kwv303

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  32 in total

Review 1.  The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis.

Authors:  Ruanne V Barnabas; Emily L Webb; Helen A Weiss; Judith N Wasserheit
Journal:  AIDS       Date:  2011-08-24       Impact factor: 4.177

2.  The clinical interpretation of viral blips in HIV patients receiving antiviral treatment: are we ready to infer poor adherence?

Authors:  Isaac C H Fung; Manoj Gambhir; Ard van Sighem; Frank de Wolf; Geoffrey P Garnett
Journal:  J Acquir Immune Defic Syndr       Date:  2012-05-01       Impact factor: 3.731

Review 3.  Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection.

Authors:  Pierre Corbeau; Jacques Reynes
Journal:  Blood       Date:  2011-03-14       Impact factor: 22.113

4.  Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.

Authors:  Michael J Mugavero; Sonia Napravnik; Stephen R Cole; Joseph J Eron; Bryan Lau; Heidi M Crane; Mari M Kitahata; James H Willig; Richard D Moore; Steven G Deeks; Michael S Saag
Journal:  Clin Infect Dis       Date:  2011-09-02       Impact factor: 9.079

5.  Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.

Authors:  Stephen R Cole; Sonia Napravnik; Michael J Mugavero; Bryan Lau; Joseph J Eron; Michael S Saag
Journal:  Am J Epidemiol       Date:  2009-12-09       Impact factor: 4.897

Review 6.  Heterosexual risk of HIV transmission per sexual act under combined antiretroviral therapy: systematic review and bayesian modeling.

Authors:  Virginie Supervie; Jean-Paul Viard; Dominique Costagliola; Romulus Breban
Journal:  Clin Infect Dis       Date:  2014-04-09       Impact factor: 9.079

7.  Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Authors:  Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

8.  Association of low level viremia with inflammation and mortality in HIV-infected adults.

Authors:  Abigail Eastburn; Rebecca Scherzer; Andrew R Zolopa; Constance Benson; Russell Tracy; Tri Do; Peter Bacchetti; Michael Shlipak; Carl Grunfeld; Phyllis C Tien
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

9.  X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process.

Authors:  Annalisa Saracino; Laura Monno; Luigia Scudeller; Giuseppe Bruno; Nicoletta Ladisa; Grazia Punzi; Anna Volpe; Antonella Lagioia; Gioacchino Angarano
Journal:  BMC Infect Dis       Date:  2013-05-16       Impact factor: 3.090

10.  Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years.

Authors:  Viviane D Lima; Juan Sierra-Madero; Zunyou Wu; Joel Singer; Evan Wood; Mark W Hull; Paul Richard Harrigan; Julio S G Montaner
Journal:  J Int AIDS Soc       Date:  2014-05-06       Impact factor: 5.396

View more
  6 in total

1.  Bias in the estimation of cumulative viremia in cohort studies of HIV-infected individuals.

Authors:  Maia Lesosky; Tracy Glass; Brian Rambau; Nei-Yuan Hsiao; Elaine J Abrams; Landon Myer
Journal:  Ann Epidemiol       Date:  2019-08-23       Impact factor: 3.797

2.  All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study.

Authors:  Olof Elvstam; Gaetano Marrone; Patrik Medstrand; Carl Johan Treutiger; Anders Sönnerborg; Magnus Gisslén; Per Björkman
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

3.  Cumulative viral load as a predictor of CD4+ T-cell response to antiretroviral therapy using Bayesian statistical models.

Authors:  Joseph B Sempa; Theresa M Rossouw; Emmanuel Lesaffre; Martin Nieuwoudt
Journal:  PLoS One       Date:  2019-11-13       Impact factor: 3.240

4.  Neurocognitive status and risk of mortality among people living with human immunodeficiency virus: an 18-year retrospective cohort study.

Authors:  Zaeema Naveed; Howard S Fox; Christopher S Wichman; Morshed Alam; Pamela May; Christine M Arcari; Jane Meza; Steven Totusek; Lorena Baccaglini
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

5.  HIV-Associated CKDs in Children and Adolescents.

Authors:  Hostensia Beng; Natella Rakhmanina; Asha Moudgil; Shamir Tuchman; Sun-Young Ahn; Caleb Griffith; Marva Moxey Mims; Patricio E Ray
Journal:  Kidney Int Rep       Date:  2020-09-08

6.  Viraemic-time predicts mortality among people living with HIV on second-line antiretroviral treatment in Myanmar: A retrospective cohort study.

Authors:  Anita Mesic; Tom Decroo; Htay Thet Mar; Bart K M Jacobs; Moe Pyae Thandar; Thin Thin Thwe; Aung Aung Kyaw; Mitchell Sangma; David Beversluis; Elkin Bermudez-Aza; Alexander Spina; Darli Po Po Aung; Erwan Piriou; Koert Ritmeijer; Josefien Van Olmen; Htun Nyunt Oo; Lutgarde Lynen
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.